ProCE Banner Activity

ECHELON-1: Phase III Trial of First-line Brentuximab Vedotin + AVD Chemotherapy in Advanced Classical Hodgkin Lymphoma

Slideset Download
Conference Coverage
Brentuximab vedotin plus AVD reduced the risk of progression, death, or need for further anticancer therapy by 23% vs standard ABVD in patients with previously untreated advanced classical Hodgkin lymphoma.

Released: December 14, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology